酶原

基本解释 (translations)

proenzyme  ·  zymogen  ·  proferment  ·  zymogenous  ·  osmogen

与酶原相关的网络例句 [注：此内容来源于网络，仅供参考]

According to the fast equilibrate assumption, a complete mathematics description was presented for elucidating the zymogen inter-autoactivation process, which can be used to determine the activation rate constant.

通过对酶原自激活的全过程的分析，给出了普遍适用的动力学方程，由于该方程的推导是建立在快速平衡假设的，因而可以不依赖于初始酶原浓度远大于酶浓度的条件。

Plasma urokinaseantigen,tissue plasminogen activator antigen, plasminogen activatoractivity, plasminogen activator inhibiter activity, plasmin activity and fibrinogen antigen Were measured before and after thrombolytic treatment with intravenous UK in 44 patients suffering from their first attack of acute myocardial infarction.

观察44例首次急性心肌梗塞患者的尿激酶静脉溶栓治疗前后血浆UK抗原、组织纤溶酶原激活物抗原、纤溶酶原激活物活性、纤溶酶原激活物抑制物活性、纤溶酶活性和纤维蛋白原抗原的变化。

Sequence analysis showed that the full-length cDNA sequence of Sc-SAMDC (GenBank Accession number: GQ246459) was 1 968 bp, with three open reading frames, tiny ORF, upstream ORF and main ORF. The mORF was 1200 bp encoding 399 amino acid residues with a molecular mass of 43.6 kD, and the deduced protein had two highly conserved function domains (proenzyme cleavage site and PEST domain).

序列分析显示，甘蔗Sc-SAMDC基因(GenBank Accession number： GQ246459) cDNA全长1968 bp，存在3个读码框（袖珍读码框tORF、上游读码框uORF和主读码框mORF），mORF长1200 bp，编码399个氨基酸的SAMDC酶原，预测分子量为43.6 kD，该酶原含有两个高度保守的功能结构域（酶原剪切位点和PEST结构域）。

Plasminogen activator inhibitor-1 (PAI-1) is a physiological inhibitor of tissue-type plasminogen activator and urokinase-type plasminogen activator .

纤溶酶原激活物抑制因子-1（PAI-1）是组织型纤溶酶原激活物和尿型溶酶原激活物的生理性抑制因子。

Plasminogen activator inhibitor-1 (PAI-1) is a physiological inhibitor of tissue-type plasminogen activator t-PA...

纤溶酶原激活物抑制因子-1（PAI-1）是组织型纤溶酶原激活物和尿型溶酶原激活物的生理性抑制因子。

Of or relating to a zymogen.

酶原的酶原的，与酶原有关的

When the activating enzyme and the activated enzyme coincide, the process is an autocatalytic zymogen activation.

如果活性酶能够催化自身酶原的活化，这一过程就称为酶原自活化。

The method uses first phase law to determine 63 DVT patient contrasts normally with 30 the F Ⅻ C of the group, use law of thing of the heart that deliver quality to detect at the same time zymogen of serous fine dissolve is active , law of enzymatic couplet immunity measures sex of antigen of content of activation of zymogen of methodize fine dissolve (depressor of content of activation of zymogen of dissolve of T-PAAg), fine - 1 antigen sex (PAI-1Ag) and immunity compare chaotic law to determine serous D-2 gets together body content.

方法采用一期法测定63例DVT患者和30例正常对照组的FⅫC，同时采用发色底物法检测血浆纤溶酶原活性，酶联免疫法测定组织型纤溶酶原激活物抗原性、纤溶酶原激活物抑制剂-1抗原性(PAI-1Ag)及免疫比浊法测定血浆D-二聚体含量。

MMPs are usually secreted as latent, inactive proenzymes, which need to be activated (Fig 1 ), and/or are bound to their native inhibitors, the tissue inhibitors of metalloproteinases.8 Activation may involve proteolysis and/or oxidation of the latent enzyme.8 Proteolytic activation of the proenzymes cleaves the propeptide sequence, which masks the active site of the latent enzyme.

金属蛋白酶常以无活性的酶原方式分泌，而后者要么需要被激活要么与附近的或组织中金属蛋白酶抑制物结合。激活作用包括了具有潜在酶的蛋白水解作用或氧化作用。酶原的蛋白水解激活作用能将掩盖活性部位的潜在酶的前肽序列破坏。

The maximum MTG activity in the culture broth was 5.04u/mL and increased by 21.8% compared with the control. With the addition of CTAB, pro-MTG was activated to become MTG. CTAB could enhance the production of pro-MTG by relieving the pr...

初步研究表明，CTAB的主要作用是促使谷氨酰胺转胺酶的酶原转化为成熟酶，因此，在发酵过程中添加适当浓度的CTAB，可使酶原快速、完全地转化为成熟的MTG，解除酶原的产物抑制作用，促进了细胞产酶。

与酶原相关的网络解释 [注：此内容来源于网络，仅供参考]

Plasminogen Activator：纤溶酶原激活物

的过程称为纤维蛋白溶解,简称纤溶.※ 纤维蛋白溶解系统 纤维蛋白溶解过程 血液生理 纤维蛋白溶解系统: 纤维蛋白溶解系统 纤维蛋白溶解酶原 (plasminogen) ) 纤维蛋白溶解酶 (plasmin) ) 纤溶酶原激活物 (plasminogen activator) ) 纤溶酶原抑制物 (plasminogen inhibitor) ) 由肝,

proenzyme：酶原[酶的无活性前体]

proenkephalin 脑啡肽原 | proenzyme 酶原[酶的无活性前体] | profibrin 血纤蛋白原

proenzyme;zymolysis：酶原 酶原

production of medicinal meterials 藥材生產 药材生产 | proenzyme;zymolysis 酶原 酶原 | progestogens; progestins 孕激素 孕激素类

proenzyme;zymogen;enzyme precursor：酵素原; 酶原

原胚细胞 proembryonal cell | 酵素原; 酶原 proenzyme;zymogen;enzyme precursor | 酵素原; 酶原 proferment;zymogen

tissue-type plasminogen activator：纤溶酶原激活物抑制剂

组织型纤溶酶原激活物:Plasminogen activator inhibtor | 纤溶酶原激活物抑制剂:Tissue-type plasminogen activator | 尿激酶型纤溶酶原激活剂:Urokinase - type plasminogen activator

tissue-type plasminosen activator：组织型纤溶酶原激活物

纤溶酶原激活物抑制剂-1:Plasminogen Activator Inhibitor-1(PAI-1) | 组织型纤溶酶原激活物:tissue-type plasminosen activator | 纤溶酶原激活物抑制物-1:plasminogen activator inhibitor-1

zymogen：酶原

输送到特定的部位,当体内需要时,经特异性蛋白水解酶的作用转变为有活性的酶而发挥作用. 这些不具催化活性的酶的前体称为酶原(zymogen). 如胃蛋白酶原(pepsinogen)、胰蛋白酶原(trypsinogen)和胰凝乳蛋白酶原(chymotrypsinogen)等.

proferment;zymogen：酵素原; 酶原

酵素原; 酶原 proenzyme;zymogen;enzyme precursor | 酵素原; 酶原 proferment;zymogen | 侧形 profile

urokinase plasminogen activator：尿激酶型纤溶酶原激活物

纤溶酶原激活物抑制剂:plasminogen activator inhibitor-1 | 尿激酶型纤溶酶原激活物:urokinase plasminogen activator | 纤溶酶原激活剂抑制物-1:Plasminogen activator inhibitor type 1

urokinase type plasminogen activator：尿激酶型纤溶酶原激活剂

纤溶酶原激活物抑制剂:Tissue-type plasminogen activator | 尿激酶型纤溶酶原激活剂:Urokinase - type plasminogen activator | 纤溶酶原激活物抑制物:plasminogen activator inhibitor-1